Biohaven enrolls first patient in Phase 3 Clinical Trial to assess Rimegepant Zydis ODT to treat Migraine

Biohaven Pharmaceuticals asserted that it has enrolled the first patient in a Phase 3 Clinical Trial of Zydis that is a orally dissolving tablet formulation of rimegepant for the profound treatment of migraine.

Rimegepant is a potent, orally available small molecule calcitonin gene-related peptide )receptor antagonist in late stage development for the treatment of migraine.

The Phase 3 Clinical Trial will evaluate the onset of action, patient satisfaction, efficacy and safety of the fast-dissolve Zydis ODT formulation of rimegepant. Biohaven has been working with Catalent U.K. Swindon Zydis Limited, a subsidiary of Catalent, Inc. to develop this new ODT formulation of rimegepant and extend additional delivery formulations across its CGRP platform.

Biohaven has ventured into an exclusive agreement with Catalent for the use of the Zydis ODT  formulation technology in the development of small molecule CGRP receptor antagonists.

Vlad Coric, M.D., Chief Executive Officer at Biohaven, commented, “Biohaven is committed to  bringing the most differentiated oral, small molecule CGRP receptor antagonist to patients suffering from migraine. The fast-dissolving Zydis ODT rimegepant formulation is designed to conveniently enable people experiencing a migraine attack to promptly initiate their acute treatment without the need for taking with liquids. We believe that rimegepant Zydis ODT has the potential to be a best-in-class therapy option for the acute treatment of migraine.”

Robert Croop, M.D., Chief Development Officer – Neurology, at Biohaven, added, “This clinical trial with the new fast-dissolve Zydis ODT formulation complements our ongoing work with rimegepant. We are very pleased to incorporate the trial into our ongoing Phase 3 clinical program. We believe that the rimegepant Zydis^® ODT will be a desirable new approach for the acute treatment of migraine.”